Roche's Genentech Announces New 72-Week Data From BALATON And COMINO, Evaluating Vabysmo In Macular Edema Due To Branch And Central Retinal Vein Occlusion
Roche's Genentech Announces New 72-Week Data From BALATON And COMINO, Evaluating Vabysmo In Macular Edema Due To Branch And Central Retinal Vein Occlusion
羅氏基因泰克公佈了來自BALATON和COMINO的72周新數據，評估了Vabysmo在分支和視網膜中央靜脈阻塞導致的黃斑水腫中的作用
Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision –
Vabysmo 持續嚴重乾燥視網膜液體，通常與視力失真或模糊有關 —
– Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months apart –
— 接受Vabysmo治療的人中有多達60％能夠將治療間隔延長至相隔三到四個月 —
– Detailed results from two global Phase III RVO studies will be presented at Angiogenesis, Exudation, and Degeneration 2024 –
— 兩項全球III期RVO研究的詳細結果將在2024年血管生成、滲出和變性上公佈
– Vabysmo is approved in the U.S. for RVO, and in more than 90 countries around the world for people living with wet AMD and DME –
— Vabysmo在美國獲准使用RVO，全球90多個國家批准用於溼性AMD和DME患者 —